Publikationen von Ashok Kumar Jayavelu
Alle Typen
Zeitschriftenartikel (8)
1.
Zeitschriftenartikel
15, 25 (2022)
Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. Journal of Hematology & Oncology 2.
Zeitschriftenartikel
40 (3), S. 301 - 317.e12 (2022)
The proteogenomic subtypes of acute myeloid leukemia. Cancer Cell 3.
Zeitschriftenartikel
131 (21), e151818 (2021)
Signaling defects associated with insulin resistance in nondiabetic and diabetic individuals and modification by sex. Journal of Clinical Investigation 4.
Zeitschriftenartikel
32 (5), S. 844 - 859.e5 (2020)
A Cell-Autonomous Signature of Dysregulated Protein Phosphorylation Underlies Muscle Insulin Resistance in Type 2 Diabetes. Cell Metabolism 5.
Zeitschriftenartikel
588, S. 157 - 163 (2020)
Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. Nature 6.
Zeitschriftenartikel
34 (5), S. 1444 - 1449 (2020)
SHP1 regulates a STAT6-ITGB3 axis in FLT3ITD-positive AML cells. LEUKEMIA 7.
Zeitschriftenartikel
8 (62), S. 105440 - 105457 (2017)
Nuclear membrane-localised NOX4D generates pro-survival ROS in FLT3-ITD-expressing AML. Oncotarget 8.
Zeitschriftenartikel
8 (16), S. 26613 - 26624 (2017)
Synergistic killing of FLT3ITD-positive AML cells by combined inhibition of tyrosine-kinase activity and N-glycosylation. Oncotarget Meeting Abstract (1)
9.
Meeting Abstract
43 (SUPPL 4), S. 36 - 37. Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020: Abstracts, 09. Oktober 2020 - 11. Oktober 2020. Karger, Basel (2020)
A single nucleotide polymorphism of the transcription factor Growth Factor Independence 1 (GFI1) accelerates AML evolution and sensitizes AML cells to treatment with DNA repair inhibitors. In Oncology Research and Treatment,